Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) has seen a rise in its stock price by 6.72% in relation to its previous close of $1.19. However, the company has experienced a 9.48% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-07-01 that SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on July 1, 2025, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 14,000 shares of the Company’s common stock to one (1) newly hired employee. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).
Is It Worth Investing in Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Right Now?
Additionally, the 36-month beta value for ZNTL is 1.70. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 6 rating it as “hold,” and 0 rating it as “sell.”
The public float for ZNTL is 55.51M and currently, short sellers hold a 10.26% ratio of that float. The average trading volume of ZNTL on July 09, 2025 was 980.36K shares.
ZNTL’s Market Performance
The stock of Zentalis Pharmaceuticals Inc (ZNTL) has seen a 9.48% increase in the past week, with a -13.61% drop in the past month, and a 8.55% gain in the past quarter. The volatility ratio for the week is 8.30%, and the volatility levels for the past 30 days are at 8.99% for ZNTL. The simple moving average for the last 20 days is -5.22% for ZNTL stock, with a simple moving average of -45.11% for the last 200 days.
Analysts’ Opinion of ZNTL
Many brokerage firms have already submitted their reports for ZNTL stocks, with Wedbush repeating the rating for ZNTL by listing it as a “Neutral.” The predicted price for ZNTL in the upcoming period, according to Wedbush is $4 based on the research report published on August 12, 2024 of the previous year 2024.
UBS, on the other hand, stated in their research note that they expect to see ZNTL reach a price target of $5, previously predicting the price at $28. The rating they have provided for ZNTL stocks is “Neutral” according to the report published on June 20th, 2024.
ZNTL Trading at -3.93% from the 50-Day Moving Average
After a stumble in the market that brought ZNTL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -76.65% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZNTL starting from Myers Scott Dunseth, who purchase 21,000 shares at the price of $1.40 back on Apr 30 ’25. After this action, Myers Scott Dunseth now owns 281,192 shares of Zentalis Pharmaceuticals Inc, valued at $29,373 using the latest closing price.
Bruns Ingmar, the Chief Medical Officer of Zentalis Pharmaceuticals Inc, purchase 20,000 shares at $2.28 during a trade that took place back on Feb 06 ’25, which means that Bruns Ingmar is holding 36,629 shares at $45,656 based on the most recent closing price.
Stock Fundamentals for ZNTL
Current profitability levels for the company are sitting at:
- -7.89 for the present operating margin
- 0.98 for the gross margin
The net margin for Zentalis Pharmaceuticals Inc stands at -8.34. The total capital return value is set at -0.63. Equity return is now at value -59.45, with -47.62 for asset returns.
Based on Zentalis Pharmaceuticals Inc (ZNTL), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at -3.92.
Currently, EBITDA for the company is -191.19 million with net debt to EBITDA at 0.02. When we switch over and look at the enterprise to sales, we see a ratio of 3.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.94.
Conclusion
In conclusion, Zentalis Pharmaceuticals Inc (ZNTL) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
